Skip to main content

Advertisement

SpringerLink
Log in

Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission

  • Original Article
  • Published:
Tumor Biology

Abstract

Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen. Treatment using rituximab in combination with chemotherapy has dramatically improved overall survival rate of diffuse large B cell lymphoma (DLBCL). Since rituximab can deplete both lymphoma B cells and normal B cells, how rituximab-treatment affects normal B cell function in DLBCL patients under remission is unclear. Here, we examined peripheral blood B cell composition and antigen-specific B cell responses in DLBCL patients in remission and observed reductions in the frequencies of total B cell as well as several major B cell subsets, including CD19+IgD+ naive B cells, CD19+IgD−CD27+ memory B cells, and CD19loCD27hi plasmablasts. Moreover, tetanus toxin (TT)-specific B cell proliferation was reduced in DLBCL patients in remission. On the other hand, HA-specific IgG-secreting B cell responses could be stimulated by influenza vaccination in DLBCL patients in remission, demonstrating that the machinery for generating de novo adaptive B cell responses was functional in DLBCL patients in remission. Our results provided insights in normal B cell function in DLBCL patients in remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Horner MJ, Ries LAG, Krapcho M, Eisner MP, Kosary CL, Hankey BF, et al. SEER Cancer Statistics Review, 1975–2006. [Internet]. Statistics (Ber). 2006. Available from: http://seer.cancer.gov/csr/1975_2002/

  2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood. 1994;83:435–45.

    CAS  PubMed  Google Scholar 

  3. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu Rev Med. 2008;59:237–50.

    Article  CAS  PubMed  Google Scholar 

  4. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.

    Article  CAS  PubMed  Google Scholar 

  5. Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–65.

    Article  CAS  PubMed  Google Scholar 

  6. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.

    Article  CAS  PubMed  Google Scholar 

  7. Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997;12:177–86.

    Article  CAS  PubMed  Google Scholar 

  8. Jung D, Giallourakis C, Mostoslavsky R, Alt FW. Mechanism and control of V(D)J recombination at the immunoglobulin heavy chain locus. Annu Rev Immunol. 2006;24:541–70.

    Article  CAS  PubMed  Google Scholar 

  9. Schatz DG, Ji Y. Recombination centres and the orchestration of V(D)J recombination. Nat Rev Immunol. 2011;11:251–63.

    Article  CAS  PubMed  Google Scholar 

  10. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595–621.

    Article  CAS  PubMed  Google Scholar 

  11. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol. 2011;29:621–63.

    Article  CAS  PubMed  Google Scholar 

  12. Allen CDC, Okada T, Cyster JG. Germinal-center organization and cellular dynamics. Immunity. 2007;27(2):190–202.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Shaffer AL, Young RM, Staudt LM. Pathogenesis of human B cell lymphomas. Annu Rev Immunol. 2012;30:565–610.

    Article  CAS  PubMed  Google Scholar 

  14. Compagno M, Lim WK, Grunn A, Nandula SV, Brahmachary M, Shen Q, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009;459:717–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Nussenzweig A, Nussenzweig MC. Origin of chromosomal translocations in lymphoid cancer. Cell. 2010;141(1):27–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9:235–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Geffroy-Luseau A, Chiron D, Descamps G, Jégo G, Amiot M, Pellat-Deceunynck C. TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. Front Immunol. 2011;2:83.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med. 2009;361:1945–52.

    Article  CAS  PubMed  Google Scholar 

  20. Harwood NE, Batista FD. Early events in B cell activation. Annu Rev Immunol. 2010;28:185–210.

    Article  CAS  PubMed  Google Scholar 

  21. Bour-jordan H, Bluestone JA. Commentaries B cell depletion : a novel therapy for autoimmune diabetes ? J Clin Invest. 2007;117:3642–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol. 2011;29:273–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67:134–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Robillard N, Avet-Loiseau H, Garand R, Moreau P, Pineau D, Rapp MJ, et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood. 2003;102:1070–1.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Author notes

    Authors and Affiliations

    1. Department of Transfusion, Changhai Hospital, Second Military Medical University, Shanghai, 200433, China

      Zhanshan Cha, Yan Zang, Haihui Gu, Huijun Guo, Jinqi Li & Baohua Qian

    2. Department of Hepatobiliary Surgery, Linyi People’s Hospital, Linyi, 276000, Shandong, China

      Chen Li

    3. BGC Biotechnology Research Center, Jinan, Shandong, China

      Yuan Fang & Thomas F. Petersen

    4. Department of Hematology, Shandong Affiliated Hospital, Shandong, China

      Jing Li

    5. School of Medicine, Wayne State University, Detroit, MI, USA

      Richard O. Karas

    6. Department of Medicine, University of Maryland, Baltimore, MD, USA

      Michele L. Hamilton

    Authors
    1. Zhanshan Cha
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Chen Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Yan Zang
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Haihui Gu
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Huijun Guo
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Jinqi Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Yuan Fang
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Thomas F. Petersen
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Jing Li
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Richard O. Karas
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Michele L. Hamilton
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Baohua Qian
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding authors

    Correspondence to Richard O. Karas, Michele L. Hamilton or Baohua Qian.

    Additional information

    Zhanshan Cha and Chen Li contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Cha, Z., Li, C., Zang, Y. et al. Adaptive B cell responses in rituximab-treated diffuse large B cell lymphoma patients during complete remission. Tumor Biol. 37, 829–835 (2016). https://doi.org/10.1007/s13277-015-3872-6

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-015-3872-6

    Keywords

    Search

    Navigation